Opportunistic and Other Infections in HIV-Infected Children in Latin America Compared to a Similar Cohort in the United States
Publication: AIDS Research and Human Retroviruses
Volume 28, Issue Number 3
Abstract
Opportunistic and other infections have declined since the introduction of highly active antiretroviral therapy (HAART) in developed countries but few studies have addressed the impact of HAART in HIV-infected children from developing countries. This study examines the prevalence and incidence of opportunistic and other infections in Latin America during the HAART era. Vertically HIV-infected children enrolled in a cohort study between 2002 and 2007 were followed for the occurrence of 29 targeted infections. Cross-sectional and longitudinal analyses were performed to calculate the prevalence of infections before enrollment and the incidence rates of opportunistic and other infections after enrollment. Comparisons were made with data from a U.S. cohort (PACTG 219C). Of the 731 vertically HIV-infected children 568 (78%) had at least one opportunistic or other infection prior to enrollment. The most prevalent infections were bacterial pneumonia, oral candidiasis, varicella, tuberculosis, herpes zoster, and Pneumocystis jiroveci pneumonia. After enrollment, the overall incidence was 23.5 per 100 person-years; the most common infections (per 100 person-years) were bacterial pneumonia (7.8), varicella (3.0), dermatophyte infections (2.9), herpes simplex (2.5), and herpes zoster (1.8). All of these incidence rates were higher than those reported in PACTG 219C. The types and relative distribution of infections among HIV-infected children in Latin America in this study are similar to those seen in the United States but the incidence rates are higher. Further research is necessary to determine the reasons for these higher rates.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Brady MTOleske JMWilliams PL et al. Pediatric AIDS Clinical Trials Group 219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART eraJ Acquir Immune Defic Syndr201053186-94.1. Brady MT, Oleske JM, Williams PL, et al.: Pediatric AIDS Clinical Trials Group 219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010;53(1):86–94.
2.
Gortmaker SLHughes MCervia J et al. Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1N Engl J Med2001345211522-1528.2. Gortmaker SL, Hughes M, Cervia J, et al.: Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345(21):1522–1528.
3.
Gona PVan Dyke RBWilliams PL et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART eraJAMA2006296292-300.3. Gona P, Van Dyke RB, Williams PL, et al.: Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006;296:292–300.
4.
Nesheim SRKapogiannis BGSoe MM et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004Pediatrics2007120100-109.4. Nesheim SR, Kapogiannis BG, Soe MM, et al.: Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004. Pediatrics 2007;120:100–109.
5.
Chiappini EGalli LTovo PA et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAARTAIDS2007211607-1615.5. Chiappini E, Galli L, Tovo PA, et al.: Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS 2007;21:1607–1615.
6.
Candiani TMPinto JCardoso CA et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, BrazilCad Saude Publica200723Suppl 3S414-423.6. Candiani TM, Pinto J, Cardoso CA, et al.: Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica 2007;23(Suppl 3):S414–423.
7.
Peña DALarrañaga LCLuchsinger FV et al. Cytomegalovirus disease in HIV-1 infected Chilean childrenRev Chil Infect200724477-484.7. Peña DA, Larrañaga LC, Luchsinger FV, et al.: Cytomegalovirus disease in HIV-1 infected Chilean children. Rev Chil Infect 2007;24:477–484.
8.
Martínez-Aguilar GVásquez de Kartzow RNava-Frias MSantos Preciado J. Infección por VIH en niños mexicanosSalud Públ México199537572-580.8. Martínez-Aguilar G, Vásquez de Kartzow R, Nava-Frias M, and Santos Preciado J: Infección por VIH en niños mexicanos. Salud Públ México 1995;37:572–580.
9.
Andino-Martinez KGodoy-Mejia C. Pediatric AIDS: Opportunistic illnesses and recurrent infectionsRev Med Post UNAH2001650-54.9. Andino-Martinez K and Godoy-Mejia C: Pediatric AIDS: Opportunistic illnesses and recurrent infections. Rev Med Post UNAH 2001;6:50–54.
10.
Hazra RStoszek SKFreimanis-Hance L et al. NISDI Pediatric Study Group 2008. Cohort Profile: NICHD International Site Development Initiative (NISDI): A prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countriesInt J Epidemiol2009381207-1214.10. Hazra R, Stoszek SK, Freimanis-Hance L, et al.: NISDI Pediatric Study Group 2008. Cohort Profile: NICHD International Site Development Initiative (NISDI): A prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countries. Int J Epidemiol 2009;38:1207–1214.
11.
An SAS program for CDC Growth Charts [Centers for Disease Control and Prevention (CDC) web site]www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htmOctober222008.11. An SAS program for CDC Growth Charts [Centers for Disease Control and Prevention (CDC) web site] Available at www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm. Accessed October 22, 2008.
12.
Caldwell MBOxtoby MJSimonds RJLindegren MLRogers MF. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of ageMMWR199443RR-121-10Preview/mmwrhtml/00032890.htm.12. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, and Rogers MF: 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12);1–10. Preview/mmwrhtml/00032890.htm.
13.
Rothman KJModern EpidemiologyLittle Brown and CompanyBoston/Toronto1986.13. Rothman KJ: Modern Epidemiology. Little Brown and Company, Boston/Toronto, 1986.
14.
Guillén SGarcía MLResino S et al. Madrid Group for Research on Pediatric HIV Infection. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990–2006)HIV Med2010114245-252.14. Guillén S, García ML, Resino S, et al.: Madrid Group for Research on Pediatric HIV Infection. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990–2006). HIV Med 2010;11(4):245–252.
15.
Mubiana-Mbewe MBolton-Moore CBanda Y et al. Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, ZambiaTrop Med Int Health2009141190-1198.15. Mubiana-Mbewe M, Bolton-Moore C, Banda Y, et al.: Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia. Trop Med Int Health 2009;14:1190–1198.
16.
Calder DQazi S. Evidence behind the WHO guidelines: Hospital care for children: What is the aetiology of pneumonia in HIV-infected children in developing countries?J Trop Pediatr200955219-224.16. Calder D and Qazi S: Evidence behind the WHO guidelines: Hospital care for children: What is the aetiology of pneumonia in HIV-infected children in developing countries? J Trop Pediatr 2009;55:219–224.
17.
Levin MJAnderson JPSeage GR 3rdWilliams PLthe PACTG/IMPAACT 219C Team. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected childrenJ Acquir Immune Defic Syndr200950182-191.17. Levin MJ, Anderson JP, Seage GR 3rd, Williams PL, and the PACTG/IMPAACT 219C Team: Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr 2009;50:182–191.
18.
Wood SMShah SSSteenhoff APRutstein RM. Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006Pediatrics2008121e150-156.18. Wood SM, Shah SS, Steenhoff AP, and Rutstein RM: Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics 2008;121:e150–156.
Information & Authors
Information
Published In
AIDS Research and Human Retroviruses
Volume 28 • Issue Number 3 • March 2012
Pages: 282 - 288
PubMed: 21902581
Copyright
Copyright 2012, Mary Ann Liebert, Inc.
History
Published online: 5 March 2012
Published in print: March 2012
Published ahead of print: 19 September 2011
Published ahead of production: 9 September 2011
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.